NCT05617755
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer No drug interventions treatment 1 active_not_recruiting NCT01462890
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer treatment 3 completed NCT00698451
A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers treatment 2 completed NCT00103545
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response prevention 1 / 2 completed NCT04556071
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer treatment 2 unknown_status NCT01313078
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer treatment 2 completed NCT01478685
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors treatment 1 completed NCT01228942
A Prospective Trial of COXEN Chemotherapy Prediction No drug interventions Not Available Not Available withdrawn NCT03976999
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers No drug interventions other Not Available recruiting NCT00445549
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer treatment 2 terminated NCT02786524
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy No drug interventions supportive_care Not Available completed NCT00443196
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas No drug interventions treatment 2 / 3 completed NCT01766622
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant No drug interventions diagnostic 2 withdrawn NCT01932125
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer treatment 4 active_not_recruiting NCT05960630
MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer No drug interventions treatment Not Available recruiting NCT04196257
BP1001-A in Patients With Advanced or Recurrent Solid Tumors treatment 1 recruiting NCT06466382
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy treatment Not Available not_yet_recruiting NCT01279291
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer treatment 1 terminated NCT03648489
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) treatment 2 unknown_status NCT00074867
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer treatment 2 completed NCT05194072
A Study of SGN-B7H4V in Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT01681368
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer treatment 2 terminated NCT00191646
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy treatment 3 completed NCT00415181
Pharmacogenomics of Paclitaxel in Ovarian Cancer No drug interventions Not Available Not Available completed NCT02658214
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors treatment 1 completed NCT05257408
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer treatment 3 active_not_recruiting NCT00189345
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients treatment 2 completed NCT01846611
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer treatment 3 completed NCT02903771
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. treatment 1 completed NCT04111978
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) treatment 3 recruiting NCT00191607
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. treatment 3 completed NCT00407407
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma treatment 1 terminated NCT00415207
Pharmacogenomics of Paclitaxel in Ovarian Cancer No drug interventions Not Available Not Available completed NCT00035100
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer treatment 2 completed NCT00391118
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") treatment 2 completed NCT04498117
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery treatment 3 active_not_recruiting NCT05605535
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer treatment 2 recruiting NCT06223763
SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery No drug interventions Not Available Not Available recruiting NCT00112086
OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 treatment 2 completed NCT01131039
Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer treatment 2 withdrawn NCT04794322
Developing a Test for the Detection of Ovarian Cancer No drug interventions Not Available Not Available recruiting NCT04807166
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer treatment 2 active_not_recruiting NCT02478476
DNA Single Nucleotide Polymorphisms as Predictors of Toxicity No drug interventions Not Available Not Available unknown_status NCT05116189
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) treatment 3 active_not_recruiting NCT03000192
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life No drug interventions Not Available Not Available unknown_status NCT00063401
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer treatment 2 completed NCT03593681
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy No drug interventions Not Available Not Available completed NCT02444195
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients No drug interventions supportive_care Not Available completed NCT00006155
SU5416 and Carboplatin to Treat Ovarian Cancer treatment 1 completed